CHMA - Chiasma Intends To Redeem Itself With Multiple Catalysts In The Coming Months

Chiasma (CHMA) announced that it had achieved positive results in a Phase 3 study using octreotide capsules (Mycapssa) for treatment of adults with acromegaly. This positive Phase 3 data will allow the biotech to file an NDA for its drug candidate in this indication by the end of 2019, which sets up a catalyst opportunity. There is another catalyst opportunity in the 2nd half of 2019. This is data released from another Phase 3 study known as MPOWERED using Mycapssa for the same population as a maintenance treatment in the European territory. All

Read more ...